Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Authors
Saad, F.Armstrong, A. J.
Thiery-Vuillemin, A.
Oya, M.
Shore, N. D.
Procopio, G.
Arslan, C.
Mehra, N.
Parnis, F.
Brown, E.
Schlurmann, F. C.
Joung, J. Y.
Sugimoto, M.
Sartor, O.
Liu, Y. Z.
Poehlein, C. H.
Desai, C.
Del Rosario, P. M. D.
Clarke, Noel W
Affiliation
Department Of Urology, Centre Hospitalier de l’Université de Montréal/CRCHUM, Université de Montreal, H2X 3J4Issue Date
2022
Metadata
Show full item recordCitation
Saad F, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore ND, Procopio G, et al. Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 2022 Sep;33(7):S1160-S. PubMed PMID: WOS:000866211601614.Journal
Annals of OncologyDOI
10.1016/annonc/annonc1070Additional Links
https://dx.doi.org/10.1016/annonc/annonc1070Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/annonc/annonc1070